SSY GROUP (02005.HK): Choline Fenofibrate Sustained-release Capsule Obtains Drug Production Registration Approval
NewTimeSpace News: SSY Group (02005.HK) released a voluntary announcement on 16 July 2026. The Group has secured the drug production registration approval from the National Medical Products Administration (NMPA) for Choline Fenofibrate Sustained-release Capsule (135mg). As a Category 4 chemical drug, it is deemed to have passed generic consistency evaluation.
On the basis of dietary control for adult patients, the product is indicated for lowering triglyceride levels in patients with severe hypertriglyceridemia, as well as treating patients with primary hypercholesterolemia or mixed dyslipidaemia.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SSY GROUP (02005.HK): Trustee Purchases 900,000 Shares for Approximately HKD 2,414,700 under Restricted Share Award Scheme
- SSY GROUP (02005.HK): Gadobutrol injection and indocyanine green for injection approved, enhancing imaging and critical care product portfolio
- SSY GROUP(02005.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 320.32 million, YoY increase of 12.99%
- SSY GROUP (02005.HK): Obtains production registration approval for sodium ozagrel injection, achieving full dosage form coverage
- SSY GROUP (02005.HK): Vitamin K1 Injection obtains NMPA drug production registration certificate, deemed to pass consistency evaluation
